Skip to main content

Table 2 Overview of the literature on the (significant) relation between biomarker and the disease activity

From: The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial

Author Population No. Biomarker Classification Results
Mullan et al.9 RA 45 C2C (baseline,1, 3, 6, 9,12-mo serum) DAS28 responders vs. nonresponders (at 3 mo) C2C ↓
  PsA 17 C1,2C (responder: ≥0.6 improvement and DAS28 ≤5.1, nonresponder: <0.6 improvement OR DAS28 > 5.1) NS
  (mean 11 yr, DAS28 > 3.2)   CPII   NS
    ΔCOL (ΔC2C + ΔC1, 2C + ΔCPII)   ΔCOL ↓
Mullan et al.9 RA 45 C2C (baseline,1, 3, 6, 9, 12-mo serum)   C2C ↓ at 1 mo
  PsA 17 C1,2C Remission vs. no remission C1,2C ↓ at 1 mo
  (mean, 11 yr,   CPII (remission = DAS28 <2.6 at 6 mo) NS
  DAS28 > 3.2)   ΔCOL (ΔC2C + ΔC1,2C + ΔCPII)   ΔCOL ↓ change 1 mo
  1. DAS28, disease activity score based on 28 joints; mo, month; NS, not significant; number, number of patients investigated in the studies; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SF, synovial fluid; yr, year.